Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

7.545
-0.905-10.71%
Volume:4.17M
Turnover:32.11M
Market Cap:7.94B
PE:-20.39
High:8.455
Open:8.455
Low:7.395
Close:8.450
52wk High:19.860
52wk Low:7.395
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:2.89
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-28.59%
ROA:-19.64%
PB:2.99
PE(LYR):-20.39
PS:7158.62

Loading ...

Ascletis Pharma Joins Two Chinese Stock Connect Programs

MT Newswires Live
·
Sep 07

Ascletis to Join Shanghai- and Shenzhen-Hong Kong Stock Connect, Unlocking Mainland Investor Access

Bulletin Express
·
Sep 07

Ascletis Announces Inclusion in the Hong Kong Stock Connect List Under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs

THOMSON REUTERS
·
Sep 07

歌礼制药-B股价早盘攀升逾8%,重磅减肥药全球III期试验迎来关键里程碑

Deep News
·
Sep 02

Sweden's Klaria Net Loss Narrows on Lower R&D Expenses

Reuters
·
Sep 01

China's United Laboratories Half-Year Profit Drops 82%

Reuters
·
Aug 31

China's Ascletis Pharma H1 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 31

Ascletis Pharma-B Reports H1 Net Loss of RMB 320 Million, Widening by 263.5% Year-on-Year

Stock News
·
Aug 31

Ascletis Pharma Inc. - Board of Directors Does not Recommend Payment of Any Dividend in Respect of Hy

THOMSON REUTERS
·
Aug 31

Ascletis Pharma FY26 H1 Net Loss More than Doubled to RMB 319.67 Million; Total Income Falls 48.9% to RMB 52.98 Million

Reuters
·
Aug 31

Ascletis Pharma H1 Net Income Attributable RMB -319.671 Million

THOMSON REUTERS
·
Aug 31

Ascletis Pharma Starts Phase III Trial of Weight-Loss Drug; Shares Plummet 5%

MT Newswires Live
·
Aug 31

Ascletis Advances ASC30: First Patient Dosed in 4,600-Subject Global Phase III Trials for Oral GLP-1 Weight-Loss Therapy

Bulletin Express
·
Aug 30

Ascletis Announces First Participant Dosed in a Global Phase Iii Clinical Program of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist Asc30 for Chronic Weight Management

THOMSON REUTERS
·
Aug 30

Ascletis Pharma - Topline Phase Iii Data Expected Q3 2028; FDA Nda by End 2028; Ema Maa Early 2029

THOMSON REUTERS
·
Aug 30

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Aug 26

Ascletis Pharma Slips on Expecting Deeper H1 Loss on R&D Expenses

Reuters
·
Aug 24

Ascletis Pharma Expects HY Loss of Rmb319.7 MLN

Reuters
·
Aug 21

Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million

Stock News
·
Aug 21

Ascletis Pharma Projects RMB319.70 Million H1 2026 Loss as R&D Spend Jumps 132.7%

Bulletin Express
·
Aug 21